Advertisement

PROTON THERAPY FOR ADULTS WITH MEDIASTINAL LYMPHOMAS: THE INTERNATIONAL LYMPHOMA RADIATION ONCOLOGY GROUP (ILROG) GUIDELINES

Bouthaina Shbib Dabaja, Bradford S. Hoppe, John P. Plastaras, Wayne Newhauser, Katerina Rosolova, Stella Flampouri, Radhe Mohan, N. George Mikhaeel, Youlia Kirova, Lena Specht and Joachim Yahalom

Abstract

Radiation treatment techniques that increase the excess radiation dose to organs at risk (OARs) puts patients at risk of increased side effects, especially late toxicities, among adults lymphoma survivors. Minimizing radiation to OARs in adults patients with Hodgkin and non-Hodgkin lymphomas involving the mediastinum is the deciding factor for the choice of treatment modality. Proton therapy may help reduce the radiation dose to the OARs and reduce toxicities, especially the risks of cardiac morbidity and second cancers. Because proton therapy may have some disadvantages, identifying the patients and the circumstances that may benefit the most from proton therapy is important. We here present the modern guidelines to identify the adult lymphoma patients who may derive the greatest benefit from proton, along with an analysis of the advantages and disadvantages of the proton treatment.

  • Submitted March 9, 2018.
  • Accepted July 19, 2018.